CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

The nitroxyl (HNO) prodrug, CXL-1020, induces vasorelaxation and improves cardiac function in canine models and patients with systolic heart failure (HF). HNO's unique mechanism of action may be applicable to a broader subset of cardiac patients. This study investigated the load-independent saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Roof, Steve R., Ueyama, Yukie, Mazhari, Reza, Hamlin, Robert L., Hartman, J. Craig, Ziolo, Mark T., Reardon, John E., del Rio, Carlos L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701606/
https://www.ncbi.nlm.nih.gov/pubmed/29209225
http://dx.doi.org/10.3389/fphys.2017.00894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701606/
https://www.ncbi.nlm.nih.gov/pubmed/29209225
http://dx.doi.org/10.3389/fphys.2017.00894

Ejemplares similares